RECRUITING

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Talk to us

Conditions

Esophageal CancerHead and Neck CancerLung CancerPrecancerous Conditionnon-small cell lung cancersmall cell lung cancersquamous lung dysplasiahypopharyngeal cancerlaryngeal cancerlip and oral cavity cancermetastatic squamous neck cancer with occult primarynasopharyngeal canceroropharyngeal cancerparanasal sinus and nasal cavity cancersalivary gland cancerpulmonary carcinoid tumortongue cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Official Title

Biomarkers and Dysplastic Respiratory Epithelium

Quick Facts

Study Start:2001-05-03
Study Completion:2026-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00900419

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of extensive and severe dysplasia of the respiratory epithelium
  2. * Those without dysplasia of the respiratory epithelium
  3. * Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)
  4. * Survived 1 or more aerodigestive system carcinoma for ≥ 1 year
  5. * Completely resected stage I non-small cell cancer
  6. * Undergoing any of the following procedures:
  7. * Routine panendoscopy for patients with head and neck cancer
  8. * Resection of a bronchogenic carcinoma
  9. * Bronchoscopy for diagnosis or staging of suspected lung cancer
  10. * Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse
  11. * No asthma
  12. * No lung disease
  13. * No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
  14. * No clinically apparent bleeding diathesis
  15. * No known bleeding disorder
  16. * No anginal
  17. * No clinically active coronary artery disease
  18. * No multifocal premature ventricular contractions
  19. * No poorly controlled congestive heart failure
  20. * No myocardial infarction within the past 6 weeks
  21. * No cardiac dysrhythmia that is potentially life threatening
  22. * Well-controlled atrial fibrillation or rare (\< 2/min) premature ventricular contractions allowed
  23. * No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response
  24. * No other serious medical condition that would preclude a patient from undergoing a bronchoscopy
  25. * No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer
  26. * No hypoxemia (i.e., \< 90% saturation with supplemental oxygen) before bronchoscopy
  27. * See Disease Characteristics
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Brandi Kubala
CONTACT
303-724-1657
brandi.kubala@cuanschutz.edu

Principal Investigator

York E. Miller, MD
PRINCIPAL_INVESTIGATOR
University of Colorado, Denver

Study Locations (Sites)

University of Colorado Cancer Center at UC Health Sciences Center
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • York E. Miller, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2001-05-03
Study Completion Date2026-09-30

Study Record Updates

Study Start Date2001-05-03
Study Completion Date2026-09-30

Terms related to this study

Keywords Provided by Researchers

  • non-small cell lung cancer
  • small cell lung cancer
  • squamous lung dysplasia
  • hypopharyngeal cancer
  • laryngeal cancer
  • lip and oral cavity cancer
  • metastatic squamous neck cancer with occult primary
  • nasopharyngeal cancer
  • oropharyngeal cancer
  • paranasal sinus and nasal cavity cancer
  • salivary gland cancer
  • esophageal cancer
  • pulmonary carcinoid tumor
  • tongue cancer

Additional Relevant MeSH Terms

  • Esophageal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Precancerous Condition